Added 8 days ago Drug news

PREPARE Phase III trial of ResVax shows efficacy in respiratory syncytial virus

Novavax announced the presentation of new data from the company’s Prepare trial, a global Phase III clinical trial of ResVax...

Added 25 days ago Drug news

Positive CHMP opinion for Epidyolex for the treatment of seizures associated with Lennox?Gastaut syndrome or Dravet syndrome

GW Pharmaceuticals plc announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted...

Added 29 days ago Drug news

Vertex Pharma files NDA at FDA for elexacaftor, tezacaftor and ivacaftor combination for F508del mutation cystic fibrosis.

Vertex Pharmaceuticals Incorporated announced the submission of a New Drug Application (NDA) to the FDA for the VX-445 (elexacaftor), tezacaftor...

Preterm labour and birth

This guideline covers the care of women at increased risk of or with symptoms and signs of preterm labour (before 37 weeks) and women having a planned preterm birth.

Added 3 years ago

Suspected neurological conditions: recognition and referral

This guideline covers the initial assessment of symptoms and signs that might indicate a neurological condition. It helps non-specialist healthcare professionals to identify people who should be offered referral for specialist investigation.

Added 5 days ago

Depression in children and young people: identification and management

This guideline covers the identification and treatment of depression in children (5–11 years) and young people (12–18 years) in primary, community and secondary care.

Added 13 years ago

Channelopathies.

Channelopathies are a heterogeneous group of disorders resulting from the dysfunction of ion channels located in the membranes of all cells and many cellular organelles. These include diseases of the nervous system (e.g., generalized epilepsy...

Added 6 days ago

In pursuit of control and elimination: update on hepatitis A and B epidemiology and prevention strategies.

Purpose of review: This review describes the impact of recommendations for routine immunization of infants and children against hepatitis A and hepatitis B, the changing epidemiology of these infections, and the remaining...

Added 1 month ago

A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.

Background: Tezacaftor/ivacaftor is a new treatment option in many regions for patients aged ≥12 years who are homozygous (F/F) or heterozygous for the F508del-CFTR mutation and a residual function (F/RF) mutation.

Added 1 month ago

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple sclerosis (RRMS) and to assess the pharmacokinetics (PK) of BIIB017 in pediatric participants...

Added 2 months ago

A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF (ANAKIN)

Primary Ojective:
- To evaluate efficacy of treatment with anakinra in subjects with CF who are ≥ 12 years of age by means of lung clearance index (LCI).

Added 1 month ago

Symdeko in Cystic Fibrosis Patients

This clinical study will enroll 22 participants without the F508del mutation, carrying partial function mutations not approved for Symdeko, and who are not expected to be approved for CFTR modulator treatment in the immediate future.

Added 1 month ago